SYNT
NEUTRALSynthomer Director Increases Stake
The Chief Executive Officer of the specialty chemicals company has purchased additional shares in the business.
Synthomer
57.90GBX
5.08%
Market Cap
94.65M
Volume
339.55k
41% of avg
P/E Ratio
4.80
EPS (TTM)
12.06
Beta
2.2
Day Range
54.30p - 58.00p
52 Week Range
45.40p57.90p180.50p
57.90p
Upcoming Events
2026
Anticipated progress in Group earnings and cash generation as a result of self-help actions and product investments
High Impact Event
2027
Next significant debt maturity
High Impact Event
SYNT
NEUTRALSynthomer PLC Announces Change in Shareholding
The specialty chemicals company has announced a change in shareholding, with Lombard Odier Asset Management (Europe) Limited increasing its stake to 5.01%.
SYNT
NEUTRALSynthomer Weathers Soft Market Conditions, Focuses on Cost Savings and Transformation
The specialty chemicals company navigates soft market conditions, focusing on cost savings and strategic initiatives to strengthen its position.
SYNT
NEUTRALSynthomer Appoints Peel Hunt as Joint Corporate Broker
The specialty chemicals company has appointed Peel Hunt LLP as a joint corporate broker, working alongside its existing broker J.P. Morgan Cazenove.
SYNT
NEUTRALSynthomer PLC Announces Change in Shareholding
The specialty chemicals company has announced a change in shareholding, with the Greater Manchester Pension Fund reducing its stake in the company.
SYNT
NEUTRALSynthomer Announces Director Share Purchase
The specialty chemicals company has announced a non-executive director has purchased 25,000 ordinary shares.
SYNT
NEUTRALSynthomer Director Increases Stake
The non-executive director of the specialty chemicals company has purchased additional shares.
SYNT
NEUTRALSynthomer plc Announces Director/PDMR Shareholding
The specialty chemicals company has announced a change in shareholding by a director.
SYNT
NEUTRALSynthomer Announces Non-Executive Director Departure
The specialty chemicals company announces the departure of an independent Non-Executive Director as part of its long-term succession planning.
SYNT
BADSynthomer Reports Challenging H1 2025 Results Amid Market Volatility
The specialty chemicals manufacturer reported declining revenues and increased net debt in H1 2025, facing volatile market conditions and geopolitical uncertainties. Cost-cutting measures are being implemented to mitigate challenges.